ST. LOUIS, Oct. 8, 2015 /PRNewswire/ -- Sigma-Aldrich
Corporation (NASDAQ: SIAL) announced today that the
Cerilliant® brand within its Applied Diagnostics and
Testing business segment has launched its new bile acid reference
standards product line with ten certified Snap-N-Spike®
solutions of the most routinely tested bile acids and their
stable-labeled internal standards. These new solution certified
reference materials (CRMs) consist of lithocholic acid, taurocholic
acid and native and deuterium-labeled analogs of cholic acid,
chenodeoxycholic acid, deoxycholic acid, and ursodeoxycholic
acid.
Mass spectrometry-based analyses of bile acids (BAs) are
performed in neonatal screening of inborn errors of BA synthesis
and therapeutic monitoring of patient responses to
therapy.1 BA analysis is also routinely conducted during
the pre-clinical phase of drug development to evaluate the
hepatotoxicity of candidate drugs.2
Research highlighting the influence of BA metabolism in the
development of gastroenterologic and hepatic diseases has led to
the need for new BA testing applications.3,4 These
emerging applications include the use of BAs as biomarkers for the
detection of biliary tract cancer, metabolic profiling of patients
with gastrointestinal disorders to optimize treatment outcomes, and
identifying additional biomarkers for liver diseases such as
obstetric cholestatis, a liver disorder associated with adverse
perinatal outcomes.3,4,5
Cerilliant offers a wide selection of Certified Spiking
Solutions® for use as starting material in the
preparation of calibrators and controls in testing applications
ranging from clinical diagnostic testing, endocrinology, and
clinical chemistry to therapeutic drug monitoring, clinical
toxicology, and pharmaceutical research. Cerilliant's catalog
offering includes solution CRMs of numerous native and
stable-labeled drugs and drug metabolites, as well as endogenous
biomarkers. Cerilliant certified reference solutions are
manufactured and certified to the highest industry standards
including ISO Guide 34, ISO/IEC 17025, and ISO 13485 and are
compliant with ISO 15194.
About Cerilliant: Cerilliant Corporation, located in
Round Rock, Texas, is a global
leader in providing certified reference standards for critical
applications. The company has been providing Certified Reference
Materials for over 35 years. Cerilliant offers more than 3,000
catalog products and a full range of custom products and services
that address the stringent and complex requirements of the
pharmaceutical, clinical diagnostic, clinical/forensic toxicology,
and natural products industries. Cerilliant sustains a modern,
robust quality system, which incorporates cGMP, GLP, and ISO
requirements. The company is accredited to ISO Guide 34 and ISO/IEC
17025, is certified to ISO 13485 and ISO 9001, and is compliant
with ISO 15194. Cerilliant Corporation is a subsidiary of
Sigma-Aldrich. For more information about Cerilliant, visit
www.cerilliant.com.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology
company focused on enhancing human health and safety, manufactures
and distributes 250,000 chemicals, biochemicals and other essential
products to more than 1.4 million customers globally in research
and applied labs as well as in industrial and commercial markets.
With three distinct business units - Research, Applied and SAFC
Commercial - Sigma-Aldrich is committed to enabling science to
improve the quality of life. The Company operates in 37 countries,
has approximately 9,700 employees worldwide and had sales of
$2.79 billion in 2014. For more
information about Sigma-Aldrich, visit www.sigma-aldrich.com.
Sigma-Aldrich, Cerilliant,
Snap-N-Spike, and Certified Spiking Solutions are registered
trademarks of Sigma-Aldrich Co. LLC or an affiliated company.
1. Jahnel, J., Zöhrer, E., Scharnagl, H., Erwa, W., Fauler, G.
and Stojakovic, T. (2015) Reference ranges of serum bile acids in
children and adolescents. Clinical Chemistry and Laboratory
Medicine (CCLM).
http://www.degruyter.com/doi/10.1515/cclm-2014-1273 (14
September 2015).
2. Van Tonder, J., Steenkamp, V.
and Gulumi, M. (2013) Pre-Clinical Assessment of the Potential
Intrinsic Hepatotoxicity of Candidate Drugs. New Insights into
Toxicity and Drug Testing, 2013: 10.5772/54792.
3. Xu, X., Cheng, S., Ding, C., Lv, Z., Chen, D. and Wu, J. et
al. (2014) Identification of bile biomarkers of biliary tract
cancer through a liquid chromatography/mass spectrometry-based
metabolomic method. Molecular Medicine Reports, 2014:
10.3892/mmr.2014.2973.
http://www.spandidos-publications.com/mmr/11/3/2191?text=fulltext (14
September 2015).
4. Holmes, E., Wijeyesekera, A., Taylor-Robinson, S. and Nicholson, J. (2015) The
promise of metabolic phenotyping in gastroenterology and
hepatology. Nature Reviews Gastroenterology &
Hepatology, 12, 458-471.
http://www.nature.com/nrgastro/journal/v12/n8/full/nrgastro.2015.114.html (14
September 2015).
5. Egan, N., Bartels, Ä., Khashan, A., Broadhurst, D., Joyce, C.
and O'Mullane, J. et al. (2012) Reference standard for serum bile
acids in pregnancy. BJOG: An International Journal of Obstetrics
& Gynaecology, 119, 493-498.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cerilliant-introduces-certified-spiking-solutions-of-bile-acids-300156271.html
SOURCE Sigma-Aldrich Corporation